Why Doctors Just Solved a 50-Year Blood Mystery to Uncover a Brand New Blood Group

Fifty-two years after a routine prenatal blood test revealed a biological anomaly that defied existing hematological catalogs, researchers have mapped the genetic sequence responsible for the AnWj blood antigen. The finding officially establishes the MAL system as the 47th human blood group recognized by the International Society of Blood Transfusion (ISBT).

The resolution of the case, published in the journal Blood by a research consortium led by NHS Blood and Transplant (NHSBT) and the University of Bristol, ends an analytical stalemate that began in 1972.

The quantitative profile of this discovery reveals an extreme immunological divide:

>99.9%: The proportion of the global population carrying the AnWj antigen on their red blood cells.
<0.001%: The estimated frequency of individuals who naturally lack the antigen due to inherited genetic deletions.
52 years: The exact duration between the initial laboratory observation of the missing antigen and its definitive genetic classification.
47: The cumulative number of recognized human blood group systems following the classification of MAL (ISBT system 047).
17 kilodaltons: The molecular mass of the elusive Mal proteolipid, a miniature tetraspan protein that evaded biochemical detection for more than five decades.
5: The number of genetically AnWj-negative individuals whose whole exome sequences ultimately broke the impasse.

THE NUMERICAL PROFILE OF BLOOD GROUP 047 (MAL)
┌──────────────────────────────────────┬─────────────────────────────────────┐
│ Metric                               │ Scientific Measurement              │
├──────────────────────────────────────┼─────────────────────────────────────┤
│ Antigen Designation                  │ AnWj (Anton / Wj)                   │
│ New Blood Group System               │ MAL (ISBT System 047)               │
│ Molecular Carrier                    │ Myelin and Lymphocyte Protein (Mal) │
│ Protein Molecular Weight             │ ~17 kDa (153 amino acids)           │
│ Chromosomal Locus                    │ Chromosome 2q11.1                   │
│ Global Population Antigen Positivity │ >99.9%                              │
│ Documented Inherited Negative Cases  │ Fewer than 10 kindreds worldwide    │
│ Primary Technical Method             │ Whole-Exome Sequencing + CRISPR     │
└──────────────────────────────────────┴─────────────────────────────────────┘

When an AnWj-negative individual is exposed to standard AnWj-positive blood during a transfusion, the recipient's immune system recognizes the ubiquitous donor antigen as foreign. This triggers an immediate or delayed acute hemolytic transfusion reaction driven by complement-fixing alloantibodies. With this new blood group discovered, transfusion services now possess the exact molecular markers required to design high-throughput genomic assays, preventing lethal mismatches in an ultra-rare cohort that was previously undetectable through DNA screening.

Chronology of an Enigma: Tracking the 1972 Index Case

The clinical origin of the AnWj investigation dates to 1972, when laboratory technicians analyzed a blood sample taken from an otherwise healthy pregnant woman. Routine crossmatching demonstrated that her serum contained an antibody that caused hemagglutination across 100% of tested donor red cell units, despite full compatibility within the ABO, Rh, Kell, Duffy, and Kidd systems. Her own erythrocytes failed to react with antibodies that agglutinated the red blood cells of every other tested donor.

The antibody was named AnWj, an acronym derived from the first two patients confirmed to generate the reactive alloantibody: "Anton" and "Wj". For the subsequent five decades, AnWj remained an orphan antigen—classified in the ISBT 901 series (the repository for high-incidence surface markers lacking a confirmed chromosomal locus or genetic identity).

THE 52-YEAR INVESTIGATIVE TIMELINE
1972 ─────────────────────────────────────────────────────────────────────────►
│ Initial index patient identified lacking a universal red cell surface marker;
│ antibody designated anti-AnWj.
1980–1999 ────────────────────────────────────────────────────────────────────►
│ Biochemical isolation fails repeatedly due to low copy number per erythrocyte;
│ antigen incorrectly hypothesized to reside on CD44.
2015 ─────────────────────────────────────────────────────────────────────────►
│ The original 1972 patient donates a follow-up sample at age 60+, supplying
│ high-integrity cellular material for modern genomic extraction.
2020–2023 ────────────────────────────────────────────────────────────────────►
│ Whole-exome sequencing of five AnWj-negative individuals across international
│ cohorts identifies shared homozygous deletions within the MAL gene.
2024 ─────────────────────────────────────────────────────────────────────────►
│ Expression vectors and gene knockouts confirm Mal is necessary and sufficient;
│ ISBT officially recognizes MAL as Blood Group System 047.

The investigation faced a fundamental challenge: the scarcity of biological specimens. Because true inherited AnWj negativity occurs at a frequency far below 1 in 100,000, researchers lacked sufficient patient cohorts to conduct classical linkage analysis. Over a 40-year period, fewer than 10 confirmed inherited AnWj-negative individuals were documented globally.

A breakthrough occurred when the original index patient from 1972 agreed to provide a fresh blood sample in 2015. This single draw provided modern molecular laboratories with viable nucleated cells, enabling direct genetic interrogation using sequencing technologies that were not available when her anomaly was first observed.

The Proteomic Bottleneck: Why the 17-kDa Mal Protein Eluded Detection

Human red blood cells are packed with structural proteins. Band 3 (anion exchanger 1) occupies roughly 1,200,000 sites per erythrocyte, while Glycophorin A accounts for approximately 1,000,000 copies. These abundant proteins form the basis of many classical blood groups, creating clear bands on polyacrylamide electrophoresis gels.

The Mal protein exhibits the opposite physical profile. Encoded by the MAL gene on chromosome 2q11.1, it is a proteolipid of 153 amino acids with a molecular mass of just 17 kDa. Structurally, it features four transmembrane alpha-helical domains that weave through the lipid bilayer, exposing only minimal hydrophilic loops to the extracellular environment.

COMPARATIVE ERYTHROCYTE SURFACE DENSITY
Protein/Blood System    Copies Per Red Blood Cell    Molecular Mass (kDa)
───────────────────────────────────────────────────────────────────────────
Band 3 (Diego)          1,200,000                    ~100 kDa
Glycophorin A (MNS)     1,000,000                    ~31 kDa
Aquaporin-1 (Colton)      160,000                    ~28 kDa
CD44 (Indian)               3,000 – 10,000           ~80–90 kDa
Mal Protein (MAL/AnWj)      1,000 – 4,000            ~17 kDa

Quantitative flow cytometry and proteomic evaluations reveal that Mal is expressed at exceptionally low copy numbers—estimated between 1,000 and 4,000 molecules per mature erythrocyte. This represents less than 0.3% of the surface abundance of Band 3. Because the extracellular loops of Mal are short and hydrophobic, antibodies directed against AnWj bind to conformational epitopes that denature when standard detergents are applied during protein purification.

For nearly two decades, academic literature hypothesized that the AnWj antigen resided on CD44, an 80-to-90 kDa cell-adhesion glycoprotein. This hypothesis was supported by circumstantial data: cord blood red cells (which express lower amounts of CD44) showed weak AnWj reactivity, and patients exhibiting the rare In(Lu) dominant inhibitor gene displayed both reduced CD44 and suppressed AnWj expression. However, biochemical assays failed to find mutations in the CD44 coding sequence of AnWj-negative patients.

As cell biologist Dr. Tim Satchwell observed regarding the technical hurdles: "Mal is a very small protein with some interesting properties which made it difficult to identify and meant we needed to pursue multiple lines of investigation to accumulate the proof we needed to establish this blood group system".

Genomic Resolution: Exome Sequencing and Functional Transfection

To bypass the limitations of physical protein extraction, the Bristol-led team deployed Whole-Exome Sequencing (WES) across five genetically AnWj-negative individuals. This cohort included the surviving 1972 index patient and members of a consanguineous Arab-Israeli family carrying the null phenotype.

GENOMIC SEQUENCING PROFILE
Cohort Size:                   5 genetically confirmed AnWj-negative patients
Mean Sequencing Depth:         >40x coverage across the human exome (~20,000 genes)
Candidate Locus Identified:    Chromosome 2q11.1 (MAL locus)
Mutation Profile:              Homozygous exonic deletions disrupting coding sequence
Confirmation Step:             Sanger sequencing across kindred pedigrees

Analysis revealed no shared pathogenic mutations within CD44 or SMYD1. Instead, the exome files pointed to chromosome 2q11.1: all five subjects exhibited identical homozygous deletions in the MAL gene. This structural variation removed key coding exons, eliminating the open reading frame and preventing the synthesis of the full-length 17-kDa proteolipid. Heterozygous carriers (such as the unaffected parents of the Arab-Israeli probands) carried one wild-type allele and one deleted allele, expressing sufficient Mal protein to type as AnWj-positive.

To confirm that the deletion in MAL directly caused the AnWj-negative phenotype, researchers conducted functional rescue experiments:

Recombinant Expression in Erythroid Progenitors: Researchers transfected human erythroleukemic K562 cell lines and CRISPR-engineered red cell lines lacking AnWj expression with normal, wild-type MAL cDNA.
Epitope Restoration: Insertion of the wild-type MAL gene restored AnWj surface expression, causing the cells to agglutinate when exposed to human anti-AnWj antibodies.
Mutant cDNA Inoculation: Introducing the deleted MAL sequence failed to generate any surface reactivity with anti-AnWj.
Antibody Cross-Inhibition: Competitive binding tests demonstrated that polyclonal anti-Mal antibodies directly blocked human anti-AnWj serum from attaching to normal donor red cells.

These functional assays confirmed that the Mal protein is both necessary and sufficient for AnWj antigen presentation. Decades of uncertainty ended, establishing MAL as the newest recognized system in human transfusion genetics.

Transfusion Risks: Alloimmunization and Hemolytic Reaction Kinetics

The identification of this blood group carries direct implications for clinical transfusion practice. Because AnWj-positive erythrocytes make up more than 99.9% of the global donor pool, an AnWj-negative patient admitted for surgery, childbirth, or oncology support faces an overwhelming mismatch risk.

TRANSFUSION REACTION CASCADE IN ANWJ MISMATCH
┌────────────────────────────────────────────────────────────────────────┐
│ AnWj-Negative Recipient (Possesses Circulating Anti-AnWj Alloantibodies)│
└───────────────────────────────────┬────────────────────────────────────┘
                                    │ Transfusion of standard unit
                                    ▼
┌────────────────────────────────────────────────────────────────────────┐
│ Donor Red Blood Cells (99.9%+ Population Carry AnWj Surface Antigen)   │
└───────────────────────────────────┬────────────────────────────────────┘
                                    │ Rapid IgG/IgM binding & complement
                                    ▼
┌────────────────────────────────────────────────────────────────────────┐
│ Complement Cascade Activation (C1q binding -> C3 convertase -> C5b-9)  │
└───────────────────────────────────┬────────────────────────────────────┘
                                    │ Intravascular lysis within 1–24 hrs
                                    ▼
┌────────────────────────────────────────────────────────────────────────┐
│ Clinical Outcomes: Free Hemoglobin Spikes, >30% Acute Kidney Injury,   │
│ Disseminated Intravascular Coagulation (DIC), Hemodynamic Collapse     │
└────────────────────────────────────────────────────────────────────────┘

When an AnWj-negative patient receives AnWj-positive blood, circulating anti-AnWj antibodies coat the transfused cells. The reaction cascade unfolds across measurable clinical milestones:

Clearance Half-Life ($T_{1/2}$): While standard transfused donor erythrocytes have a mean half-life of 28 to 35 days, incompatible AnWj-positive cells in an AnWj-sensitized patient are cleared from circulation within 1 to 24 hours.
Hemolysis Pathway: The anti-AnWj antibody triggers classical complement fixation. C1q binding drives the assembly of the membrane attack complex (C5b-9), causing intravascular lysis that releases free hemoglobin into plasma.
Renal and Systemic Toxicity: Free plasma hemoglobin levels spike rapidly, overwhelming haptoglobin-binding capacity (>150 mg/dL). This causes hemoglobiunuria and microvascular thrombosis, with acute kidney injury (AKI) rates exceeding 30% in unmanaged cases.

The medical literature documents the severity of these events. In a documented case involving an AnWj-negative patient who developed life-threatening auto-anti-AnWj-mediated hemolysis, clinicians administered sutimlimab—a monoclonal antibody that inhibits the C1s enzyme in the classical complement pathway. The therapy successfully arrested intravascular red cell destruction, demonstrating that complement activation is the primary driver of AnWj-related hemolytic reactions.

"The work was difficult because the genetic cases are very rare," said Dr. Louise Tilley, Senior Research Scientist at NHSBT, who pursued the project for two decades. "It represents a huge achievement, and the culmination of a long team effort, to finally establish this new blood group system and be able to offer the best care to rare, but important, patients".

IMMUNOLOGICAL PROFILE: ANTI-AnWj ANTIBODIES
Characteristic               Observed Parameter
───────────────────────────────────────────────────────────────────────────
Immunoglobulin Class         Predominantly IgG (IgG1 and IgG3 subclasses);
                             occasional IgM components observed
Complement Fixation          High (robust activation to C5b-9 complex)
Optimal Reaction Temperature 37°C (Indirect Antiglobulin Test phase)
Enzyme Sensitivity           Papain: Resistant; Ficin: Resistant;
                             Pronase: Sensitive; DTT: Sensitive
Clinical Significance        Severe acute and delayed hemolytic reactions

Acquired vs. Inherited Negativity: The Oncology Dynamic

The genetic discovery also resolves a long-standing diagnostic challenge: the stark difference between inherited and acquired AnWj-negative phenotypes.

DUAL PATHOPHYSIOLOGY OF THE AnWj-NEGATIVE PHENOTYPE
┌────────────────────────────────────────────────────────────────────────┐
│                       AnWj Antigen Status                              │
└───────────────────┬────────────────────────────────┬───────────────────┘
                    │                                │
                    ▼                                ▼
       INHERITED MAL NULL (<10%)             ACQUIRED SUPPRESSION (>90%)
┌──────────────────────────────────────┐ ┌───────────────────────────────┐
│ • Homozygous deletion of MAL gene    │ │ • Wild-type, normal MAL genes │
│ • Complete life-long absence of Mal  │ │ • Epigenetic/malignancy-driven│
│ • Individuals are hematologically    │ │ • Found in leukemias, Hodgkin │
│   healthy                            │ │   lymphoma, and MDS           │
│ • Develop stable, alloimmune anti-   │ │ • Often transient; can form   │
│   AnWj following exposure            │ │   destructive autoantibodies  │
└──────────────────────────────────────┘ └───────────────────────────────┘

More than 90% of AnWj-negative blood samples evaluated in reference laboratories do not stem from inherited mutations. Instead, they represent acquired phenotypic suppression triggered by hematological malignancies or myelodysplastic syndromes.

In patients with aggressive B-cell lymphomas, acute myeloid leukemias, or severe myeloproliferative disorders, red blood cell lineages can downregulate surface proteins. Because Mal expression is already modest (~1,000–4,000 copies per cell), pathological transcriptional suppression quickly drives surface levels below the detection threshold of hemagglutination assays.

This biological difference carries major diagnostic implications:

Inherited MAL-Null Patients: These individuals carry homozygous exonic deletions in MAL. They are hematologically healthy, maintain normal red blood cell morphologies and lifespans, and show normal complete blood counts. However, their immune systems treat transfused AnWj-positive red cells as foreign, producing durable alloantibodies.
Acquired AnWj-Suppressed Patients: These individuals possess intact, wild-type MAL genes. The loss of the antigen is secondary to bone marrow disruption. As their immune systems experience dysregulation, they may produce destructive auto-anti-AnWj antibodies that attack their own remaining AnWj-bearing cells, worsening clinical anemia.

Before this new blood group discovered by British and international researchers provided a concrete genetic biomarker, differentiating these two groups required extensive, time-consuming serological workups. Today, a single targeted genomic assay can sequence the MAL locus in under four hours, establishing whether a patient has an inherited deletion or an acquired condition requiring cancer screening.

Quantitative Landscape of the 47 Blood Group Systems

With the formal addition of MAL by the International Society of Blood Transfusion, the map of human erythrocyte surface variation expands to 47 defined systems containing more than 360 individual antigens.

The rate of discovery has shifted significantly over time. Between 1900 and 1960, blood groups were identified primarily through serological observations following transfusion mismatches or hemolytic disease of the newborn. Over the past twenty years, advances in high-throughput sequencing and targeted gene editing have driven the molecular resolution of historically intractable antigens.

THE EXPANDING BLOOD GROUP UNIVERSE: RECENT ADDITIONS (2012–2024)
ISBT  System Name  Symbol  Gene Marker  Chromosomal Locus  Year Assigned
───────────────────────────────────────────────────────────────────────────
032   Junior       JR      ABCG2        4q22.1             2012
033   Langereis    LAN     ABCB6        2q35               2012
034   Vel          VEL     SMIM1        1p36.32            2013
035   CD59         CD59    CD59         11p13              2014
036   Augustine    AUG     SLC29A1      6p21.1             2016
044   Er           ER      PIEZO1       16q24.3            2022
047   MAL          MAL     MAL          2q11.1             2024

SYSTEM ARCHITECTURE OF REPRESENTATIVE BLOOD GROUPS
┌────────────┬──────┬─────────┬──────────────┬───────────────┬────────────┐
│ Blood Group│ ISBT │ System  │ Gene / Locus │ Protein Class │ No. of     │
│ System     │ No.  │ Symbol  │              │ & Function    │ Antigens   │
├────────────┼──────┼─────────┼──────────────┼───────────────┼────────────┤
│ ABO        │ 001  │ ABO     │ ABO (9q34.2) │ Glycosyl-     │ 4          │
│            │      │         │              │ transferase   │            │
├────────────┼──────┼─────────┼──────────────┼───────────────┼────────────┤
│ MNS        │ 002  │ MNS     │ GYPA, GYPB   │ Single-pass   │ 50         │
│            │      │         │ (4q31.21)    │ glycophorin   │            │
├────────────┼──────┼─────────┼──────────────┼───────────────┼────────────┤
│ Rh         │ 004  │ RH      │ RHD, RHCE    │ 12-pass ion/  │ 56         │
│            │      │         │ (1p36.11)    │ gas transport │            │
├────────────┼──────┼─────────┼──────────────┼───────────────┼────────────┤
│ Kell       │ 006  │ KEL     │ KEL (7q34)   │ Single-pass   │ 36         │
│            │      │         │              │ endopeptidase │            │
├────────────┼──────┼─────────┼──────────────┼───────────────┼────────────┤
│ Duffy      │ 008  │ FY      │ ACKR1 (1q23) │ 7-pass GPCR / │ 6          │
│            │      │         │              │ chemokine rcpt│            │
├────────────┼──────┼─────────┼──────────────┼───────────────┼────────────┤
│ Er         │ 044  │ ER      │ PIEZO1       │ Mechanosensory│ 5          │
│            │      │         │ (16q24.3)    │ ion channel   │            │
├────────────┼──────┼─────────┼──────────────┼───────────────┼────────────┤
│ MAL        │ 047  │ MAL     │ MAL (2q11.1) │ 4-pass myelin-│ 1          │
│            │      │         │              │ lymphocyte PL │            │
└────────────┴──────┴─────────┴──────────────┴───────────────┴────────────┘

The table highlights how structural complexity varies across blood groups. The Rh system features 56 distinct antigens produced through alternate splicing, gene conversions, and point mutations across two duplicated genes (RHD and RHCE). In contrast, the newly characterized MAL system functions through a single high-prevalence antigen (AnWj) displayed across four membrane passes of a single proteolipid.

Because the AnWj marker is carried on an essential membrane proteolipid, total genetic absence has virtually no impact on basic red cell stability. However, even minor molecular variations in this region can trigger dramatic immune responses if unrecognized during transfusion.

The Economics and Operations of Rare Donor Registries

Integrating MAL into standard blood banking operations shifts screening from traditional serological tests to scalable molecular assays.

Traditional serological phenotyping for rare antigens relies on polyclonal human antisera sourced from sensitized patients. This material is scarce, costly, and yields variable potency between batches. Testing a single donor unit via standard indirect antiglobulin testing (IAT) costs $15 to $30 and requires trained laboratory personnel. By contrast, modern multiplex genotyping platforms (such as MALDI-TOF mass spectrometry or targeted Next-Generation Sequencing arrays) can evaluate 40 or more blood systems simultaneously for $40 to $75 per donor sample.

OPERATIONAL METRICS: SEROLOGICAL VS. GENOTYPIC SCREENING
Feature                  Serological Phenotyping     Multiplex Molecular Panels
───────────────────────────────────────────────────────────────────────────────
Throughput Capacity      ~20–50 samples/technician/day  >1,000 samples/run/instrument
Cost Per Antigen Point   $15.00 – $30.00             $0.80 – $1.85 (multiplexed)
Reagent Supply Chain     Scarce human antisera       Synthetic oligonucleotide primers
False-Negative Rate      2.1% (operator-dependent)   <0.01% (high analytical depth)
MAL Evaluation Feasible  No (requires rare antisera) Yes (probe added to assay)

The global donor matching mathematics illustrate why automated molecular screening is essential:

$$\text{Probability of Random Match } (P) = 1 - \text{Freq}(\text{AnWj-Positive}) = 1 - 0.999 = 0.001 \text{ (or } <1 \text{ in } 1,000\text{)}$$

When considering real-world kindreds, the actual frequency of inherited AnWj negativity is far lower than 1 in 1,000—falling below 1 in 100,000 in non-consanguineous populations. With an estimated 118.5 million blood donations collected globally each year, fewer than 1,000 units carry the inherited AnWj-negative phenotype.

THE RARE BLOOD STORAGE MODEL (CRYOPRESERVATION)
Parameter                Standard Liquid Storage     Cryopreservation (Liquid N₂)
───────────────────────────────────────────────────────────────────────────────
Storage Temperature      1°C to 6°C                  -80°C to -196°C
Anticoagulant / Solution CPD / AS-1 or SAGM          40% Glycerol w/v Cryoprotectant
Maximum Safe Shelf Life  42 Days                     30+ Years
Deglycerolization Step   Not Required                High-Speed Wash (Saline Series)
Post-Thaw Recovery Rate  N/A                         >85% Viable Red Cells
Operational Target       Routine Surgery & Trauma    Ultra-Rare Global Match Banks

Because matching units are extremely rare, international blood services rely on cryopreservation networks. Normal red blood cells stored in liquid solution must be discarded after 42 days. When a rare donor—such as an AnWj-negative individual—is identified, their red cells are treated with a 40% weight-to-volume glycerol solution to prevent ice crystal formation and frozen at temperatures below -80°C.

Cryopreservation extends the functional shelf life of these units beyond 30 years. When a sensitized AnWj-negative patient experiences an acute hemorrhage anywhere in the world, these frozen units are thawed, washed with graded saline to extract the glycerol, and flown directly to the recipient hospital through coordinated international registries.

Diagnostic Integration: Clinical Workflows for Transfusion Facilities

The molecular characterization of MAL allows hospital transfusion services to adopt a systematic diagnostic pipeline. Previously, resolving an unexplained high-incidence crossmatch incompatibility took several weeks of reference laboratory testing. Today, diagnostic centers follow a structured, multi-tier protocol:

DIAGNOSTIC DECISION PIPELINE FOR SUSPECTED AnWj INCOMPATIBILITY
┌─────────────────────────────────────────────────────────────────────────┐
│ Patient Serum Agglutinates 100% of Commercial Screen Cells (Pan-Reactive)│
└────────────────────────────────────┬────────────────────────────────────┘
                                     │
                                     ▼
┌─────────────────────────────────────────────────────────────────────────┐
│ Perform Autocontrol & Direct Antiglobulin Test (DAT)                   │
├────────────────────────────────────┬────────────────────────────────────┤
│ Positive DAT                       │ Negative DAT                       │
│ (Points to Autoantibodies)         │ (Points to Potential Alloantibody) │
└──────────────────┬─────────────────┴───────────────────┬────────────────┘
                   │                                     │
                   ▼                                     ▼
┌──────────────────────────────────────┐ ┌────────────────────────────────┐
│ Suspect Secondary Acquired Mal Loss  │ │ Suspect Inherited MAL Null     │
│ • Order oncology workup (MDS,        │ │ • Order targeted MAL exonic PCR│
│   lymphoma, leukemia screen)         │ │ • Screen siblings & consan-    │
│ • Administer immunosuppressants or   │ │   guineous relatives           │
│   complement inhibitors if hemolytic │ │ • Request rare units from      │
│ • Monitor for transient expression   │ │   national cryo-registries     │
└──────────────────────────────────────┘ └────────────────────────────────┘

Protocol Steps for Reference Laboratories

Pan-Reactivity Triage: When patient serum shows pan-reactivity against standard panel cells, laboratories crossmatch the sample against known AnWj-negative red cells. If these rare cells are non-reactive, the serum is marked as containing suspected anti-AnWj antibodies.
Exonic Deletion PCR: Technicians extract genomic DNA from peripheral blood leukocytes and run targeted primers across exons 2 and 3 of the MAL gene. Homozygous deletion confirms an inherited null phenotype.
Registry Flagging: The patient is registered in international rare donor files (such as the American Rare Donor Program or the IBGRL repository), preventing future incompatible transfusions and identifying eligible family members who could serve as donors.
Oncology Cross-Check: If sequencing shows intact wild-type MAL alleles despite an AnWj-negative serological profile, clinicians immediately initiate an oncology workup to screen for underlying hematological disease.

Future Horizons: Synthetic Red Cells, CRISPR Knockouts, and Unmapped Antigens

The characterization of MAL marks a key milestone in transfusion biology, but several biological questions remain unresolved.

ISBT WORKING STATUS: THE SEARCH FOR REMAINING ANTIGENS
Category                          Current Status / Count
───────────────────────────────────────────────────────────────────────────
Officially Recognized Systems     47 Systems (System 001 ABO through 047 MAL)
Total Cataloged Antigens          362 Antigens
ISBT 700 Series (Low Prevalence)  17 Antigens lacking assigned gene loci
ISBT 901 Series (High Prevalence) 6 Antigens lacking assigned gene loci
Next Milestones                   CRISPR-edited cultured erythrocytes (Universal cells)

The success of the Bristol consortium provides a roadmap for analyzing the remaining orphan antigens on the ISBT working lists. Currently, the ISBT 700 series contains 17 low-frequency antigens whose genetic roots remain unmapped, while the 901 series contains six high-frequency markers that lack defined chromosomal loci.

Beyond diagnostic screening, the identification of MAL advances efforts in synthetic red blood cell engineering. Research teams at the University of Bristol and NHSBT are developing methods to manufacture lab-grown red blood cells from cultured CD34+ hematopoietic stem cells. Using CRISPR-Cas9 base editing, bioengineers can target and knock out common antigenic targets—such as ABO, Rh, Kell, and Duffy—to construct universal donor red cells.

Understanding how the Mal protein behaves in red cell membranes ensures that these bioengineered cells can be safely modified without compromising their structural integrity. Because Mal-deficient red blood cells function normally in vivo, gene-editing therapies can safely evaluate whether silencing the MAL gene could yield AnWj-negative units on demand, eliminating the need to search for ultra-rare living donors.

Decades of work were required to identify this system because inherited cases are exceptionally rare and the Mal protein is expressed at minimal levels on red cells. Now that the genetic sequence is mapped, the findings move from research laboratories into routine transfusion medicine.

As global blood systems transition from serological phenotyping to multiplex genomic screening, the discovery of the MAL system ensures that even the rarest blood types can be identified, tracked, and safely transfused.